SGLT2 inhibition in heart failure with reduced or preserved ejection fraction
Dr. Mahesh Vasani
MD (Medicine),
General Medicine Doctor, Internal Medicine
Doctor in Bhavnagar, Gujarat.
Sodium-glucose transport inhibitors (SGLT2i) are effective in heart failure patients with ejection fraction (EF) <40% and left ventricular EF >40%. They should be initiated across a wide range of EFs and renal function in patients with HF and diabetes. SGLT2i is well-tolerated in most clinical HF scenarios, regardless of LVEF, glomerular filtration rate, diabetic status, or acuteness of the setting. However, implementing SGLT2i in routine practice remains a significant challenge.